Physician profile
Candice James
NPI 1952914418
$2,014.95
in general payments reported to CMS, 2019-2025
22 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $388 · 2022: $367 · 2023: $318 · 2024: $545 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $565.65 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $222.94 | 2021-2025 | |
| Lilly USA, LLC | $194.72 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $169.16 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $143.02 | 2021-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $118.32 | 2023-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $83.26 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.55 | 2021-2024 | Jardiance |
| Lundbeck LLC | $60.05 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.72 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $50.26 | 2021 | |
| Exact Sciences Corporation | $41.04 | 2023 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $38.76 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.99 | 2024-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $29.02 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.14 | 2025 | Obsidio |
| Otsuka America Pharmaceutical, INC. | $22.69 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $20.77 | 2024 | Austedo Xr |
| Avanir Pharmaceuticals, INC. | $17.02 | 2022 | |
| Ardelyx, INC. | $16.53 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $15.54 | 2022 | |
| Inogen, INC. | $8.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.